Market Cap: $13.12B
EI
Exelixis, Inc.
EXEL
NASDAQ (NASDAQ Global Select)USD
Market Cap: $13.12B
KEY DATA FROM STELLAR-303 TRIAL ENCOURAGES FUTURE STRATEGIES POSITIVE FINDINGS OPEN DOORS FOR COLLABORATION AND PARTNERSHIPS CONCLUSION In an ever-evolving pharmaceutical landscape, Exelixis' developm…
Exelixis Faces Divergent Analyst Perspectives Amidst Competitive Biopharmaceutical Landscape Exelixis, a prominent player in the biopharmaceutical sector, has recently attracted significant attention…
Evolving Perspectives on Exelixis's Future in Biopharma In recent months, Exelixis Inc. receives heightened attention from a diverse group of analysts, each offering unique insights into the company's…
Exelixis' Strategic Position in Oncology Advances with Promising Insights into Pelareorep Exelixis, a prominent player in the oncology sector, remains keenly attuned to the evolving landscape of cance…
Oncolytics Biotech Poised for Breakthrough in Oncology Treatments Oncolytics Biotech Inc. makes significant strides in the oncology sector with focused efforts on its registrational programs for anal…
Oncolytics Biotech Advances Therapeutic Options in Oncology Oncolytics Biotech Inc. is strategically positioned to influence the expanding global oncology market, which is anticipated to surge from $2…
Exelixis Focuses on Advancing Cancer Treatments Amid Industry Earnings Reports In the ever-evolving landscape of biotechnology, Exelixis is strategically positioned to leverage its innovative cancer t…
Exelixis Enhances Focus on Revenue Growth Amid Earnings Season As the earnings season unfolds, Exelixis remains in the spotlight for its commitment to advancing its pipeline of cancer therapies and dr…
Exelixis Focuses on Advancements in Cancer Treatment Amid Earnings Reports In the current landscape of biopharmaceutical developments, Exelixis stands out as it continues to make significant strides i…
Exelixis Faces Increased Investor Skepticism Amid Rising Short Interest Exelixis Inc., a prominent player in the biotechnology sector, is currently experiencing a notable rise in short interest, indic…
Groundbreaking Efficacy of Combination Therapy in Advanced Renal Cell Carcinoma In a significant development within the oncology landscape, Merck & Co. Inc. and Eisai announce impressive topline resul…
Emerging Treatment Paradigms in Renal Cell Carcinoma: A New Era for Patients In the evolving landscape of oncology, the recent results from the Phase 3 LITESPARK-011 trial by Merck & Co. Inc. and Eisa…
Emerging Breakthroughs in Renal Cell Carcinoma Treatment: A New Dual Regimen Recent findings from the Phase 3 LITESPARK-011 trial, conducted by Merck & Co. Inc. and Eisai, reveal a promising dual oral…
Biomarin Pharmaceutical's Strategic Focus on Rare Genetic Diseases: A Promising Path Forward Biomarin Pharmaceutical (NASDAQ:BMRN) is actively reinforcing its commitment to the development of therapie…
Exelixis Expands Focus on Innovative Cancer Therapies Amid Competitive Landscape Exelixis, a leader in the oncology sector, remains committed to advancing its portfolio of cancer therapies, particular…
Exelixis Faces Setback Amid Disappointing Trial Results Exelixis Inc. experiences significant market turbulence, with shares dropping 11% following the announcement of disappointing results from a key…
Exelixis Faces Setback with Disappointing Trial Results In recent developments, Exelixis Inc. experiences a significant downturn following the announcement of disappointing results from its colorectal…
Exelixis Navigates a Complex Biopharmaceutical Landscape in Analyst Evaluations In the past three months, Exelixis, Inc. (EXEL) has garnered attention from 17 analysts who provide a spectrum of evalua…
Exelixis Faces Diverse Analyst Evaluations Amidst Competitive Biopharmaceutical Landscape In recent months, Exelixis, Inc. finds itself at the center of varied evaluations from a group of 17 analysts…
Exelixis Navigates Analyst Evaluations Amid Biopharmaceutical Challenges In recent months, Exelixis, Inc. (EXEL) finds itself at a critical juncture as 17 analysts provide their assessments of the com…
Exelixis Faces Scrutiny Following Q2 Financial Report and Study Setback Exelixis, Inc. is currently under investigation by the Schall Law Firm for potential violations of securities laws, prompted by…
Exelixis Faces Legal Scrutiny Amidst Challenging Drug Performance Exelixis, Inc. is currently under scrutiny from the Schall Law Firm, which is investigating potential securities law violations linked…
Exact Sciences Prepares for Earnings Report Amidst Strategic Developments in Cancer Diagnostics Exact Sciences Corporation, a leader in the biotechnology sector specializing in innovative cancer scree…
Exact Sciences: Pivotal Earnings Report Set to Illuminate Future Path Exact Sciences Corporation, a prominent player in the biotechnology field, prepares to unveil its quarterly earnings report on Aug…
Exact Sciences Prepares for Key Earnings Report Amid Industry Innovations Exact Sciences Corporation, a prominent player in the biotechnology sector, is poised to release its quarterly earnings report…
Exelixis Faces Challenges Amid Market Optimism In a fluctuating financial landscape, Exelixis, a key player in the biopharmaceutical arena, encounters headwinds as it reports disappointing sales figur…
Exelixis Faces Challenges Amidst Broader Market Optimism Exelixis, a notable player in the biopharmaceutical sector, currently grapples with significant challenges following disappointing sales of its…
Exelixis Faces Challenges Amidst Broader Market Optimism In a landscape where major U.S. stock indices are experiencing a modest retreat from record highs, Exelixis finds itself grappling with signifi…
Exelixis Faces Diverse Analyst Opinions Amidst Industry Challenges Exelixis, a key player in the biotechnology sector, currently navigates a complex landscape characterized by mixed analyst ratings th…
Navigating Mixed Analyst Perspectives on Exelixis’ Future Exelixis, a prominent player in the biotechnology sector, faces a diverse array of analyst ratings that reveal a complex outlook on its future…
Exelixis Advances Oncology Treatment with Promising Trial Results Exelixis, Inc. announces significant progress in its oncology drug development following the topline results from the STELLAR-303 phas…
Exelixis Advances Cancer Treatment with Promising Phase 3 Trial Results Exelixis, Inc. (EXEL) recently announces significant topline results from its STELLAR-303 phase 3 pivotal trial, which investiga…
Exelixis Faces Divergent Analyst Opinions Amidst Competitive Biotech Landscape Exelixis, a key player in the biotechnology sector, currently finds itself at a crossroads, as recent analyst evaluations…
Exelixis Faces Diverging Analyst Opinions Amidst Industry Challenges In the past three months, Exelixis, a prominent player in the biotechnology sector, garners a mixed bag of analyst ratings that ref…
Exelixis Focuses on Advancing Cancer Treatments Amid Market Fluctuations Exelixis Inc. is making notable strides in the oncology sector, concentrating on developing innovative treatments for cancer. T…
Exelixis Reports Strong Earnings, Boosting Full-Year Guidance Exelixis, a biotechnology company specializing in cancer therapies, experiences a significant surge in stock price following its recent ea…
Exelixis Reports Strong Earnings, Raises Full-Year Guidance Amid Positive Market Sentiment Exelixis, a biotechnology company focused on cancer therapeutics, experiences a significant boost in its stoc…
Exelixis Exceeds Expectations and Raises Guidance Amid Strong Earnings Report Exelixis, a biotechnology company focused on developing innovative cancer therapies, recently reports a robust financial p…
Exelixis Reports Strong Financial Performance and Growth Prospects in Oncology Exelixis, Inc. showcases significant financial success for the fourth quarter and fiscal year of 2024, revealing a robust…
Exelixis Charts a Promising Path in Oncology with Strong Financial Performance and Pipeline Advancements Exelixis, Inc. demonstrates a remarkable trajectory as it reports its financial results for the…
Exelixis Prepares for Q4 2024 Financial Results Announcement Exelixis, Inc. is set to release its fourth quarter and full year financial results for 2024 on February 11, 2025, after the market closes.…
Exelixis Sets Stage for Fourth Quarter and Full Year 2024 Financial Results Exelixis, Inc. is poised to release its fourth quarter and full year 2024 financial results on February 11, 2025, following…
Exelixis Set to Showcase Innovations in Oncology at J.P. Morgan Conference Exelixis, Inc., a prominent player in the oncology sector, prepares to present a corporate overview at the upcoming 43rd Annu…
Exelixis Advances Oncology Commitment at J.P. Morgan Healthcare Conference Exelixis, Inc., a prominent player in the oncology sector, prepares to showcase its strategic vision and advancements at the…
### Advancing Cancer Immunotherapy: Sairopa and Exelixis Forge Ahead with Innovative Antibody Development Sairopa B.V. reaches a significant milestone in its collaboration with Exelixis, Inc. through…
Exelixis Partners with Sairopa to Advance Immunotherapy Research Exelixis, Inc. collaborates with Sairopa B.V. in a noteworthy clinical development agreement focused on ADU-1805, a novel anti-SIRPα an…
Exelixis Showcases Commitment to Oncology at Upcoming Investor Conferences Exelixis, Inc., an innovative oncology company based in Alameda, California, is gearing up for significant presentations at t…
Exelixis Advances in Neuroendocrine Tumor Treatment with Cabozantinib Exelixis, Inc. is poised for a significant milestone as it prepares for an upcoming discussion with the U.S. Food and Drug Adminis…
Exelixis Advances Cabozantinib for Neuroendocrine Tumors with Upcoming FDA Review Exelixis, Inc. is set to make significant strides in oncology with its supplemental New Drug Application (sNDA) for ca…
Exelixis Strengthens Position in Oncology with Robust Revenue Growth and Strategic Collaborations Exelixis, Inc. (Nasdaq: EXEL) reports impressive financial results for the third quarter of 2024, illu…